Condition
Age-associated Memory Impairment
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
80% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 2 (1)
Trial Status
Completed4
Unknown1
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05910047Not ApplicableCompletedPrimary
Supplemental Hydrogen Plus PQQ for Mitochondrial Biomarkers and Brain Function in Elderly With Mild Cognitive Impairment
NCT05759910Not ApplicableCompletedPrimary
Effect of BrainPhyt High Dose on Cognitive Function in Healthy Older Individuals
NCT05934344Not ApplicableUnknown
Effectiveness of an Intervention Using Observation/Action Therapy Among Patients With Mild Cognitive Impairment
NCT05462782Not ApplicableTerminatedPrimary
TMS for Investigating Memory Facilitation
NCT00355550Phase 2CompletedPrimary
Tricaprilin In Age-Associated Memory Impairment
NCT01429103CompletedPrimary
Hormones and Cognition in the Menopausal Transition
Showing all 6 trials